We recently published a list of Why These 10 Stocks Soared Today. In this article, we are going to take a look at where ...

Adjusted EBITDA improved significantly to $-16.2 million compared to $-43.9 million in Q1 2024, representing a $27.8 million ...

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point ...

Tempus AI shares rose after a Q1 beat, as an analyst highlighted its AI-driven growth, expanding pharma deals, and $1B+ ...

Tempus AI reassured investors that its major pharma contracts remain strong despite funding and tariff pressures.

Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter, with year-over-year revenue up 75.4 ...

Lefkofsky announced a three-year, $200 million data and modeling license agreement with AstraZeneca and Pathos to build the world’s largest foundation model in oncology. This agreement increased ...

Elizabeth Krutoholow; VP, Investor Relations; Tempus AI Inc. Jim Rogers; Chief Financial Officer; Tempus AI Inc. Eric Lefkofsky; Chief Executive Officer, Director; T ...

CompanyOverview|NASDAQ:TEM] Tempus AI (NASDAQ: TEM) is an interesting AI story that operates a platform and library for ...

FN Media Group News Commentary - Artificial Intelligence (AI) is becoming more essential in the medical markets every day, it seems. AI algorithms have demonstrated the capability to analyze vast ...